tradingkey.logo
搜尋

Jupiter Neurosciences Inc

JUNS
添加自選
0.338USD
-0.011-3.29%
收盤 05/15, 16:00美東報價延遲15分鐘
11.64M總市值
虧損本益比TTM

Jupiter Neurosciences Inc

0.338
-0.011-3.29%
查看詳細走勢圖
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-3.29%

5天

+1.56%

1月

-15.25%

6月

-74.78%

今年開始到現在

-66.86%

1年

-42.23%

TradingKey Jupiter Neurosciences Inc股票評分

單位: USD 更新時間: 2026-05-15

操作建議

Jupiter Neurosciences Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名205/382位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為25.00。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Jupiter Neurosciences Inc評分

相關信息

行業排名
205 / 382
全市場排名
419 / 4482
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Jupiter Neurosciences Inc亮點

亮點風險
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
業績增長期
公司處於發展階段,最新年度總收入21.80K美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入21.80K美元
估值高估
公司最新PE估值-1.29,處於3年歷史高位
機構加倉
最新機構持股2.06M股,環比增加42.85%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉0.00股

分析師目標

基於 1 分析師
買入
評級
25.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Jupiter Neurosciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Jupiter Neurosciences Inc簡介

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
公司代碼JUNS
公司Jupiter Neurosciences Inc
CEORosen (Christer)
網址https://jupiterneurosciences.com/
KeyAI